↓ Skip to main content

Dove Medical Press

Article Metrics

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, February 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

policy
1 policy source
twitter
1 tweeter
googleplus
1 Google+ user

Citations

dimensions_citation
64 Dimensions

Readers on

mendeley
93 Mendeley
citeulike
1 CiteULike
Title
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
Published in
International Journal of Chronic Obstructive Pulmonary Disease, February 2014
DOI 10.2147/copd.s51592
Pubmed ID
Authors

Walter Vincken, Joseph Aumann, Hungta Chen, Michelle Henley, Danny McBryan, Pankaj Goyal

Abstract

Addition of a second bronchodilator from a different pharmacological class may benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) whose symptoms are insufficiently controlled by bronchodilator monotherapy. GLOW6 evaluated the efficacy and safety of once-daily coadministration of the long-acting β2-agonist indacaterol (IND) and the long-acting muscarinic antagonist glycopyrronium (GLY) versus IND alone in patients with moderate-to-severe COPD.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 2%
United States 1 1%
Unknown 90 97%

Demographic breakdown

Readers by professional status Count As %
Other 12 13%
Student > Bachelor 12 13%
Student > Master 11 12%
Researcher 11 12%
Student > Ph. D. Student 8 9%
Other 22 24%
Unknown 17 18%
Readers by discipline Count As %
Medicine and Dentistry 48 52%
Nursing and Health Professions 7 8%
Biochemistry, Genetics and Molecular Biology 4 4%
Agricultural and Biological Sciences 4 4%
Pharmacology, Toxicology and Pharmaceutical Science 2 2%
Other 4 4%
Unknown 24 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2019.
All research outputs
#3,527,930
of 13,976,883 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#447
of 1,715 outputs
Outputs of similar age
#44,994
of 188,292 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#8
of 25 outputs
Altmetric has tracked 13,976,883 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,715 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,292 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.